Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them. Send request.
BIOTRONIK ASIA PACIFIC PTE. LTD.
Class D medical device
BIOTRONIK SE & Co. KG
Iperia 5/7 is part of a family of implantable cardioverter defibrillators (ICDs). The primary objective of the therapy is to prevent sudden cardiac death. Furthermore, the device is capable of treating bradycardia arrhythmias and cardiac resynchronization therapy with multisite ventricular pacing. The implantation of an ICD is a symptomatic therapy with the following objectives: Termination of spontaneous ventricular fibrillation (VF) through shock delivery; Termination of spontaneous ventricular tachycardia (VT) through antitachycardia pacing (ATP); in case of ineffective ATP or hemodynamically not tolerated VT, with shock delivery; Cardiac resynchronization through multisite ventricular pacing (triple-chamber devices); Compensation of bradycardia through ventricular (single; chamber devices) or AV sequential pacing (DX, dual- and triple-chamber devices)